We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current QIA market cap is 9.38B. The company's latest EPS is USD 2.1245 and P/E is 20.13.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.53B | 1.87B | 2.25B | 2.14B | 1.97B |
| Operating Income | -47.45M | 383.92M | 635.68M | 533.32M | 417.23M |
| Net Income | -69.77M | 73.64M | 537.05M | 575.66M | 484.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.26B | 5.93B | 6.21B | 6.35B | 6.17B |
| Total Liabilities | 2.94B | 3.45B | 3.35B | 2.96B | 2.31B |
| Total Equity | 2.32B | 2.48B | 2.86B | 3.39B | 3.87B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 367.03M | 492.27M | 675.99M | 751.12M | 492.78M |
| Investing | -236.96M | -503.06M | -211.7M | -735.58M | -94.53M |
| Financing | -661.75M | -74.32M | -177.8M | -152.65M | -460.61M |
| Market Cap | 9.38B |
| Price to Earnings Ratio | 20.13 |
| Price to Sales Ratio | 4.97 |
| Price to Cash Ratio | 14.63 |
| Price to Book Ratio | 2.52 |
| Dividend Yield | - |
| Shares Outstanding | 228.2M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.35 (0.84%) |
| Company Name | Qiagen NV |
| Address |
hulsterweg 82 venlo, limburg 5912-PL |
| Website | https://www.qiagen.com |
| Industry | biogenetic (human) (H4) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
